Por motivos de mantenimiento se ha deshabilitado el inicio de sesión temporalmente. Rogamos disculpen las molestias.
Artículo
Hemopatch® is effective and safe to use real-world data from a prospective European registry study
Autor/es | Lombardo, Carlo
Lopez-Ben, Santiago Boggi, Ugo Gutowski, Piotr Hrbac, Tomas Krska, Lukas Márquez-Rivas, Javier Russello, Domenico York, Elisa Zacharias, Mario |
Departamento | Universidad de Sevilla. Departamento de Cirugía |
Fecha de publicación | 2022-08-20 |
Fecha de depósito | 2023-05-30 |
Publicado en |
|
Resumen | Surgical procedures are often impeded by bleeding and/or leakage of body fluids. These complications cannot always be resolved by conventional surgical techniques. Hemopatch® is a hemostatic patch that also functions as a ... Surgical procedures are often impeded by bleeding and/or leakage of body fluids. These complications cannot always be resolved by conventional surgical techniques. Hemopatch® is a hemostatic patch that also functions as a sealant. Here we document the effectiveness and safety of Hemopatch® for routine procedures of multiple surgical disciplines. To this end, we performed a prospective, multicenter, single-arm, observational registry study. Patients were eligible if they had received Hemopatch® during an open or minimally invasive procedure in one of these specialties: hepatobiliary, cardiovascular, urological, neurological/spinal, general, or lung surgery. Patients were excluded if they had a known hypersensitivity to bovine proteins or brilliant blue, intraoperative pulsatile or severe bleeding and/or infection at the target application site (TAS). The primary endpoint for intraoperative effectiveness was hemostasis assessed as the percentage of patients achieving hemostasis within 2 min and the percentage of patients achieving hemostasis without re-bleeding at the time of surgical closure. The registry enrolled 621 patients at 23 study sites in six European countries. Six hundred twenty patients had completed follow-up information. Hemostasis within 2 min was achieved at 463 (74.5%) of all 621 TASs. Hemostasis without re-bleeding was observed at 620 (99.8%) TASs. Adverse events were reported in 64 patients (10.3%). This Hemopatch® registry shows that Hemopatch® efficiently establishes hemostasis and sealing in a variety of surgical specialties, including minimally invasive procedures. Furthermore, we provide evidence for the safety of Hemopatch® across all the specialties included in the registry. This study is registered at clinicaltrials.gov: NCT03392662. |
Agencias financiadoras | Baxter Baxter Healthcare SA, Zurich, Switzerland Universita di Pisa within the CRUI-CARE Agreement |
Cita | Lombardo, C., Lopez-Ben, S., Boggi, U., Gutowski, P., Hrbac, T., Krska, L.,...,Zacharias, M. (2022). Hemopatch® is effective and safe to use real-world data from a prospective European registry study. Updates in Surgery, 74 (5), 1521-1531. https://doi.org/10.1007/s13304-022-01353-y. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Hemopatch® is effective and safe ... | 681.3Kb | [PDF] | Ver/ | |